{"analyses":[{"groupDescription":"Week 1 Through Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Fisher Exact"},{"groupDescription":"Week 1 Through Week 48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.75","upperLimit":"43.42","value":"35.3"},{"groupId":"OG001","lowerLimit":"2.95","upperLimit":"16.40","value":"7.9"}]}],"title":"Week 1 Through Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.29","upperLimit":"49.41","value":"41.2"},{"groupId":"OG001","lowerLimit":"4.66","upperLimit":"19.69","value":"10.5"}]}],"title":"Week 1 Through Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"A mean hgb increase of ≥ 1.0 g/dL was analyzed as the percentage of participants with a hgb increase ≥ 1.0 g/dL compared with baseline (after applying the 14/3 day rule) that was sustained over any consecutive 56-day (8-week) period in the absence of RBC transfusions during the treatment period. (Week 1 through Week 24 and Week 1 through Week 48).","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Week 1 though Week 24 and Week 1 through 48","title":"Percentage of Participants Who Achieved a Mean Hemoglobin (Hgb) Increase of at Least 1.0 g/dL Over Any Consecutive 56-Day Period in Absence of Red Blood Cells (RBC) Transfusions","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}